Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.090
+0.080 (3.98%)
Mar 31, 2026, 10:07 AM EDT - Market open
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or -53.33% compared to the previous year.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$4,122,028
Market Cap
59.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -8 | -53.33% | 7 | 0 |
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| MindWalk Holdings | 102 |
| ImmuCell | 84 |
| OnKure Therapeutics | 45 |
| Mereo BioPharma Group | 39 |
| eXoZymes | 31 |
| iBio, Inc. | 20 |
| ImageneBio | 15 |
ANVS News
- 2 hours ago - Annovis Publishes Historical Review of Buntanetap in The Scientist - GlobeNewsWire
- 12 days ago - Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - GlobeNewsWire
- 12 days ago - NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - GlobeNewsWire
- 15 days ago - Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - GlobeNewsWire
- 6 weeks ago - Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - GlobeNewsWire
- 3 months ago - Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewsWire